T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
GDS Holdings
GDS
$6.97B
| $271K | ﹤0.01% |
5,756
+80
| +1% | +$4.41K |
|
2627
Northern Oil and Gas
NOG
$2.61B
| $271K | ﹤0.01% |
13,187
-3,616
| -22% | -$80.8K |
|
2628
Talos Energy
TALO
$2.58B
| $271K | ﹤0.01% |
27,663
-600
| -2% | -$6.84K |
|
|
WW
2629
DELISTED
WW International
WW
| $271K | ﹤0.01% |
16,821
-11,200
| -40% | -$201K |
|
2630
Park Aerospace
PKE
$811M
| $270K | ﹤0.01% |
20,458
-400
| -2% | -$5.37K |
|
|
FRTA
2631
DELISTED
Forterra, Inc
FRTA
| $270K | ﹤0.01% |
+11,372
| New | +$271K |
|
|
SLCA
2632
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $268K | ﹤0.01% |
28,493
+10,955
| +62% | +$109K |
|
|
IMGN
2633
DELISTED
Immunogen Inc
IMGN
| $268K | ﹤0.01% |
36,073
-51,615
| -59% | -$321K |
|
|
MITT
2634
TPG Mortgage Investment Trust
MITT
$214M
| $267K | ﹤0.01% |
26,000
| – | – |
|
2635
BioXcel Therapeutics
BTAI
$34.9M
| $266K | ﹤0.01% |
816
+148
| +22% | +$63.5K |
|
|
KLRS
2636
Kalaris Therapeutics
KLRS
$92.4M
| $266K | ﹤0.01% |
+895
| New | +$415K |
|
2637
Pure Cycle
PCYO
$273M
| $265K | ﹤0.01% |
18,164
-342
| -2% | -$5.12K |
|
2638
SI-BONE Inc
SIBN
$849M
| $265K | ﹤0.01% |
11,952
-106
| -0.9% | -$2.28K |
|
2639
Clean Energy Fuels
CLNE
$395M
| $264K | ﹤0.01% |
43,004
-33,705
| -44% | -$264K |
|
2640
Universal Technical Institute
UTI
$1.42B
| $264K | ﹤0.01% |
33,800
| – | – |
|
2641
VSE Corp
VSEC
$6.48B
| $264K | ﹤0.01% |
4,335
-200
| -4% | -$11.2K |
|
2642
Western New England Bancorp
WNEB
$282M
| $264K | ﹤0.01% |
30,100
| – | – |
|
2643
Aligos Therapeutics
ALGS
$42.3M
| $262K | ﹤0.01% |
883
-208
| -19% | -$75.9K |
|
2644
Blink Charging
BLNK
$87.1M
| $262K | ﹤0.01% |
9,883
-10,507
| -52% | -$338K |
|
|
SPNE
2645
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $260K | ﹤0.01% |
19,118
-500
| -3% | -$7.18K |
|
2646
Lemonade
LMND
$4.1B
| $259K | ﹤0.01% |
6,158
-768
| -11% | -$43.2K |
|
2647
Vera Bradley
VRA
$94.7M
| $259K | ﹤0.01% |
30,441
-400
| -1% | -$3.85K |
|
2648
First Interstate BancSystem
FIBK
$3.7B
| $258K | ﹤0.01% |
6,341
-739
| -10% | -$30.7K |
|
2649
IES Holdings
IESC
$14.9B
| $258K | ﹤0.01% |
+5,100
| New | +$255K |
|
2650
Ribbon Communications
RBBN
$377M
| $258K | ﹤0.01% |
42,674
-1,058
| -2% | -$6.27K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.